AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05182788 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHOLESWISE pressed candy
Description: consume 2 tablets per day for 8 weeks
Study NCT06062979 — intervention group
Intervention type: DRUG
Intervention: rilpivirine/cabotegravir
Description: WWH is currently providing Cabenuva treatment as a treatment option for eligible patients. The purpose of the proposed study is to use an observational, prospective cohort design to further investigate the delivery of Cabenuva among two subpopulations of WWH patients.
Study NCT05405439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3823 tablets
Description: TQB3823 tablet is an inhibitor of poly ADP-ribose polymerase (PARP).
Study NCT05405439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets
Description: Abiraterone acetate tablet is an inhibitor of cytochrome P450 17（CYP17）
Study NCT05405439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone acetate tablets
Description: Prednisone acetate tablet is a kind of glucocorticoids
Study NCT06179576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect to Baby
Description: To engage both fathers and mothers, CTB recruits parents at the time of birth, capitalizing on the magic moment of delivery, and uses father-inclusive digital media content to engage men. A key innovation lies in the introduction and rehearsal of four interaction skills -- Noticing, Following, Talking, and Encouraging (NiFTE, pronounced Nifty) -- to foster serve-and-return interactions with infants as well as supportive, cooperative coparenting interactions between mothers and fathers. To maximize program uptake, CTB is situated within an early education program parents already trust and attend. Additionally, the study will test hybrid program delivery with both in-person and remote sessions using video-enabled tablets to reduce scheduling and logistical barriers and thereby enhance retention.
Study NCT06261177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Description: 45 mins per day for the duration of 4 weeks (20 sessions).
Study NCT06261177 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham FES
Description: Sham FES
Study NCT05020327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Graded Oral Amoxicillin Challenge
Description: Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval
Study NCT05020327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-labelling in electronic medical record
Description: Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
Study NCT05020327 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: De-labelling in electronic medical record
Description: Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
Study NCT06233188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthogantic surgery
Description: surgery that correcting the maxilla and mandible related with each other
Study NCT05020327 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Referral to Allergy Immunology/Retention of Allergy Label
Description: Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
Study NCT05020327 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to Allergy Immunology/Retention of Allergy Label
Description: Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
Study NCT04984434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F182112
Description: Eight dose cohorts: 0.01, 0.1, 0.3, 1, 3, 10, 20 and 30 μg/kg) d1 treat every weeks.
Study NCT05062005 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Induction Chemotherapy
Description: Induction regimens: TP (docetaxel 75 mg/m²; cisplatin 75 mg/m²) Q3w, TPF (docetaxel 60 mg/m²; cisplatin 60 mg/m²; 5-fluorouracil 600-750 mg/m² per day, continuous intravenous infusion d1-5) Q3w, or GP (gemcitabine: 1000 mg/m2 d1, d8; cisplatin 80 mg/m2) Q3w.
Study NCT05062005 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Concurrent Chemotherapy
Description: Cisplatin 100 mg/m², Q3w.
Study NCT05062005 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Definitive Radiotherapy
Description: For all patients, the prescribed dose is 66-70 Gy (once a day, 5 times a week).
Study NCT04930523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elongation Longitudinaux Avec Decoaption Osteo Articulaire
Description: Pre physiotherapy treatment~Gym (treadmill ,cycling,vibrator) according to ability and condition of patient Shortwave diathermy SWD for atleast 10 mins Decompression treatment i.e. Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes.~Post physiotherapy treatment~Conventional Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension,by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~No exercises or walk were guided for home (till 24 hrs) Low back exs guided i.e knee to chest, pelvic rolling, bridging, SLR, pirformis exs is guided for home plan along with precautions.~No exertion ,drive carefully Avoid stairs climbing ,twisting ,bending ,weight lifting
Study NCT04930523 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Pre physiotherapy treatment~Gym (treadmill ,cycling, vibrator) according to ability and condition of patient Shortwave diathermy SWD for at least 10 minutes. ELDOA positions are guided and performed by patients before decompression Low back exercises guided i.e. knee to chest, pelvic rolling, bridging, SLR, piriformis exercises is guided for home plan along with precautions.~Decoarctation of (C0/C1/C2),(C4/C5),(C5,C6),(C6/C7),(T4/T5),(T6/T7),(T8,/T9),(L4/L5),(L5/S1) Neuro-oxy motorized lumbar spinal decompression therapy for 25 minutes. Post physiotherapy treatment Tens and infrared heat for 10 minutes at low back region. TENS is modality to reduce pain and tension, by stimulating large diameter afferent fiber .IR give superficial heat for circulation and relaxation of muscles.~ELDOA exercises(positions)are guided for home plan after session (after 24 hrs) No exertion ,drive carefully Avoid stairs climbing, twisting bending, weight lifting
Study NCT06172686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg).
Description: The first arm will receive Piperaquine tablets, that will be administered orally. Sub-curative regimen will be given as two tablets of 320mg and 160mg (total of 480mg).
Study NCT06172686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days.
Description: The second arm will receive Doxycycline (100mg tablets strength as Doxycycline hyclate) that will also be administered orally. Sub-curative regimen will be given as 1 tablet (100mg) once daily for 7 days.
Study NCT04581486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal-Massive Intervention
Description: Multimodal intervention based on 3 main measures: a) optimal fluid viscosity adaptation (with Nutilis Clear®), b) optimal nutritional support with a triple adaptation of food (texture, (Nutilis Clear®)) caloric and protein content, organoleptic) + ONS depending on nutritional status and evaluation and c) optimal treatment of oral hygiene (tooth brushing + antiseptic mouthwash + professional dental cleaning).
Study NCT04581486 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control (standard clinical practice)
Description: Standard clinical practice (fluid adaptation with Nutilis Powder® and simple texture adaptation (for solids (Nutilis Powder®))
Study NCT04909489 — intervention group
Intervention type: OTHER
Intervention: cross-sectional study without intervention
Description: cross-sectional study without intervention
Study NCT05055505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Take home saliva kits
Description: Saliva kits will be made available at schools for pick up to support symptomatic testing using PCR for students, staff and family members.
Study NCT06061939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction training with Oclussion Cuff.
Description: A strength training program with blood flow restriction will be performed for 12 weeks, with 30-45 minute sessions on Mondays, Wednesdays and Fridays. Each session includes a warm-up, the main part with specific exercises and a cool-down with stretching.
Study NCT05313035 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 protein subunit recombinant vaccine
Description: candidate vaccine manufactured by PT. Bio Farma
Study NCT05313035 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the placebo is NaCl injection manufactured by PT. Bio Farma
Study NCT06198205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fundamental motor skills
Description: This will receive fundamental motor skills(FMS) program include 12 basic motor skills(running,hopping,galloping,leaping,jumping,sliding,strinking,dribbling,catching overhand throwing and underhand rolling)
Study NCT06198205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular after school program
Description: This group will receive regular afterschool programs unstructured child's free play which include sliding, hide and seek, sea-saw, and running along with reading, drawing. Each intervention session lasted 60 minutes. The study will be conducted in the duration of 8 weeks with 3 sessions per week (total 24 sessions) will be given to the students.
Study NCT05480930 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paper-based clinical decision support (dCDS) tool
Description: The paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
Study NCT05480930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: digital clinical decision support (dCDS) tool
Description: The intervention is a digitized version of the paper based clinical decision support tools currently employed at the TMDS that are used to triage, assess and generate treatment plans for pediatric patients.
Study NCT06272552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROMs and PREMs
Description: Participants are administered PROMs and PREMs at a given timeline adequate to each participant conditions for a duration of 2 years. The administration of PROMs is done by email using the REDCap platform. The research team and health care professionals have access to their patient\&amp;amp;#39;s results to aid in the patients clinical care.~Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.
Study NCT06272552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PREMs
Description: Participants are administered a PREM once a year for two years. Only health care administrators, department heads and researchers will have access to the PREMs data, and this data will always be aggregated data to avoid identification of the patients. The administration of the PREM is done by email using the REDCap platform.~At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.
Study NCT06272552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: At recruitment and once a year, participants answer an evaluation questionnaire to measure the impact of completing PROMs and PREMs. This questionnaire is completed during a clinic visit.
Study NCT06272552 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Healthcare professionals
Description: Healthcare professionals participating in the study answer an evaluation questionnaire before the implementation starts at their service and two years later to measure their perceptions about the implementation.
Study NCT05079451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS
Description: 3BNC117-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
Study NCT05079451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-1074-LS
Description: 10-1074-LS will be administered by intravenous infusion (directly into the participants vein) over a period of 30 to 60 minutes. The total time needed to administer the study drug may be longer, based on factors such as participant tolerance. The participant's dose will be calculated using their most current weight on record.
Study NCT02055196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: carboxylesterase-expressing allogeneic neural stem cells
Description: Given via intracerebral catheter
Study NCT02055196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT02055196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT06408480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neonatologist-performed lung ultrasound
Description: lung ultrasound conducted in min 5, 15, 30, 60 min after birth in late preterm and term infants
Study NCT05641181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRB4101
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.
Study NCT04822870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quadratus lumborum block
Description: Quadratus lumborum block is an effective nerve block method in post-cesarean section analgesia. It is a relatively new technique that may provide analgesic effect in somatic pain and visceral pain, but has not been verified yet.
Study NCT04822870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iliohypogastric/ilioinguinal nerve block
Description: Iliohypogastric/ilioinguinal nerve block is a widely used nerve block technique. It can provide somatic analgesia effect in post-cesarean section.
Study NCT04822870 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural analgesia
Description: Epidural analgesia is a traditional analgesia method. Epidural morphine can provide effective analgesia but may cause plenty adverse effect.
Study NCT05641181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After the participants who signed the informed consent have been screened by the inclusion criteria, those who meet the inclusion criteria and those who do not meet the exclusion criteria will receive the following 6 dose groups in order from low to high:~100mg, 200 mg, 400 mg, 800 mg, 1200 mg, 1600 mg In each dose group, 8 participants will be enrolled to receive the drug, including 6 receiving CRB4101 tablets and 2 receiving placebo.
Study NCT05612152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to Quitline
Description: An electronic referral to the state quitline is placed. This prompts the quitline to proactively call the patient to enroll in counseling services.
Study NCT05612152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choose2Quit
Description: An electronic referral to the Choose2quit tobacco cessation navigator is placed. This prompts the navigator to call the patient to review options for tobacco cessation counseling, tobacco cessation medications and other supports.
Study NCT04838951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDO-AID CADe
Description: ENDO-AID CADe will be used during the withdrawal process of the colonoscopy.
Study NCT04898439 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: greening of the school environment
Description: The school will be greened and biodiversity will be increased. This will be done on the playground and area around the school. Special needs corners for playing, relaxing or gardening will be installed.
Study NCT05331677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: correction of deformities around the knee with external fixator
Description: minimally invasive surgery
Study NCT06401239 — intervention group
Intervention type: OTHER
Intervention: Dyadic expectations about the ARF survivor's perceived health 6 months after hospital discharge
Description: Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
Study NCT06401239 — intervention group
Intervention type: OTHER
Intervention: Self-efficacy
Description: Self-efficacy in both dyad members will be assessed at 3- and 6-month follow-up assessments using the Generalized Self-Efficacy Scale (GSE). The GSE has 10 items scored on a 4-point scale. U.S. adult population norms are available.
Study NCT06401239 — intervention group
Intervention type: OTHER
Intervention: Concordant expectations/shared appraisal of ARF survivor's health 6 months after hospital discharge
Description: Dyad members' expectations will be collected at baseline and at 3- month follow-up assessments using a visual analogue scale (VAS) ranging from 0 - 100, similar to the EQ-5D-VAS.
Study NCT06237959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Keranat™
Description: 300 mg/capsule(proso millet and wheat extract 600 mg/day)
Study NCT06237959 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 300 mg/capsule(600 mg/day as placebo)
Study NCT04955717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis and Neisseria gonorrhoeae screening using the GeneXpert
Description: Chlamydia trachomatis and Neisseria gonorrhoeae testing using the GeneXpert
Study NCT05449184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Eustachian Tuboplasty with Tympanostomy Tube Insertion
Description: Under local or general anesthesia, insert a balloon into one Eaustachian tube and inflate it for up to two minutes. The balloon is then removed. Subsequently, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
Study NCT05449184 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tympanostomy Tube Insertion
Description: Under local or general anesthesia, pierce the tympanic membrane in the front and lower quadrants, suck the tympanic effusion, and then insert a tympanic ventilation tube. The tube will be removed 6 months later.
Study NCT05204446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROW Project
Description: (GROW Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week.
Study NCT05204446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GROW+ Project
Description: (GROW+ Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention.
Study NCT05563610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500mg
Description: Patients screened to be low risk of penicillin allergy will be randomized to receive amoxicillin dose or not
Study NCT04675333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evorpacept
Description: IV Q3W
Study NCT04675333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV Q3W
Study NCT04675333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: IV Q3W
Study NCT04675333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin; 5FU
Description: IV Q3W
Study NCT04675333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/Carboplatin; 5FU
Description: IV Q3W
Study NCT05640440 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Executive function testing
Description: Assessment of executive function subdivision